Emrullah Yilmaz

6.0k total citations · 1 hit paper
57 papers, 1.7k citations indexed

About

Emrullah Yilmaz is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Emrullah Yilmaz has authored 57 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 17 papers in Otorhinolaryngology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Emrullah Yilmaz's work include Cancer Immunotherapy and Biomarkers (17 papers), Head and Neck Cancer Studies (17 papers) and Lung Cancer Treatments and Mutations (10 papers). Emrullah Yilmaz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Head and Neck Cancer Studies (17 papers) and Lung Cancer Treatments and Mutations (10 papers). Emrullah Yilmaz collaborates with scholars based in United States, Japan and South Korea. Emrullah Yilmaz's co-authors include Anuj Goenka, Andrew Kaufman, Agnès Viale, Fang Fang, Jason T. Huse, Ingo K. Mellinghoff, Craig B. Thompson, Armida W. M. Fabius, Patrick S. Ward and Luc G.T. Morris and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Emrullah Yilmaz

52 papers receiving 1.7k citations

Hit Papers

IDH1 mutation is sufficie... 2012 2026 2016 2021 2012 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
    2012 1.4k citations Emrullah Yilmaz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emrullah Yilmaz United States 12 986 768 712 327 254 57 1.7k
Anuj Goenka United States 13 933 0.9× 923 1.2× 760 1.1× 198 0.6× 478 1.9× 40 2.0k
Rolf Warta Germany 21 532 0.5× 347 0.5× 324 0.5× 335 1.0× 226 0.9× 53 1.2k
Timothy A. Chan United States 9 1.4k 1.4× 964 1.3× 863 1.2× 357 1.1× 302 1.2× 13 2.2k
Debyani Chakravarty United States 17 856 0.9× 264 0.3× 776 1.1× 602 1.8× 411 1.6× 35 1.9k
Binish Rasheed United States 19 1.5k 1.6× 1.4k 1.8× 708 1.0× 622 1.9× 405 1.6× 33 2.6k
David Tran United States 20 528 0.5× 568 0.7× 255 0.4× 485 1.5× 253 1.0× 39 1.4k
Diana Mandelker United States 23 1.3k 1.3× 319 0.4× 718 1.0× 867 2.7× 482 1.9× 94 2.5k
Koichi Yoshikawa Japan 14 601 0.6× 472 0.6× 267 0.4× 518 1.6× 499 2.0× 45 1.7k
S. Fracchioli Italy 24 938 1.0× 985 1.3× 424 0.6× 661 2.0× 123 0.5× 36 2.1k
Ingrid Moen Norway 8 393 0.4× 263 0.3× 415 0.6× 187 0.6× 139 0.5× 16 934

Countries citing papers authored by Emrullah Yilmaz

Since Specialization
Citations

This map shows the geographic impact of Emrullah Yilmaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emrullah Yilmaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emrullah Yilmaz more than expected).

Fields of papers citing papers by Emrullah Yilmaz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emrullah Yilmaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emrullah Yilmaz. The network helps show where Emrullah Yilmaz may publish in the future.

Co-authorship network of co-authors of Emrullah Yilmaz

This figure shows the co-authorship network connecting the top 25 collaborators of Emrullah Yilmaz. A scholar is included among the top collaborators of Emrullah Yilmaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emrullah Yilmaz. Emrullah Yilmaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yap, Timothy A., Olivier Rixe, Capucine Baldini, et al.. (2025). First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors. Cancer. 131(13). e35939–e35939. 2 indexed citations
2.
3.
Fan, Cong, J.L. Geiger, Tamara A. Sussman, et al.. (2024). Plasma circulating tumor DNA in patients with cutaneous squamous cell carcinoma: Initial experience.. Journal of Clinical Oncology. 42(16_suppl). e15034–e15034. 1 indexed citations
4.
Swiecicki, Paul, Emrullah Yilmaz, Ari J. Rosenberg, et al.. (2024). Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer. Journal of Clinical Oncology. 43(5). 578–588. 9 indexed citations
5.
Ullah, Fauzia, et al.. (2024). Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges. JCO Oncology Practice. 20(12). 1588–1595. 11 indexed citations
6.
Rixe, Olivier, John L. Villano, Robert Wesolowski, et al.. (2024). A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas. Clinical Cancer Research. 30(22). 5053–5060. 1 indexed citations
7.
Swiecicki, Paul, Emrullah Yilmaz, Ari J. Rosenberg, et al.. (2024). Enfortumab Vedotin (EV) in the Previously Treated Advanced Head and Neck Cancer (HNC) Cohort of EV-202. International Journal of Radiation Oncology*Biology*Physics. 118(5). e18–e18. 1 indexed citations
8.
Yang, Kailin, Shauna R. Campbell, N.M. Woody, et al.. (2023). Comparison of real‐world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials. Head & Neck. 45(4). 862–871. 3 indexed citations
9.
Yilmaz, Emrullah, et al.. (2023). Immunotherapy in HPV-Related Oropharyngeal Cancers. Current Treatment Options in Oncology. 24(3). 170–183. 12 indexed citations
10.
Hanna, Glenn J., John M. Kaczmar, Dan P. Zandberg, et al.. (2023). 922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. Annals of Oncology. 34. S582–S583. 3 indexed citations
11.
Yilmaz, Emrullah, Nofisat Ismaila, Raetasha Dabney, Nabil F. Saba, & Loren K. Mell. (2023). Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline Q and A. JCO Oncology Practice. 19(4). 194–196. 3 indexed citations
12.
Dima, Danai, Robert R. Lorenz, B. Prendes, et al.. (2023). Immunotherapy response in patients with cutaneous squamous cell carcinoma of head and neck with cranial nerve involvement. Head & Neck. 45(8). 2149–2154. 3 indexed citations
13.
Sharma, Harsh, et al.. (2023). Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control. Journal of Cancer Research and Clinical Oncology. 149(11). 8673–8680. 3 indexed citations
14.
Wu, Shannon S., Eric Lamarre, Joseph Scharpf, et al.. (2023). Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors. Endocrine Practice. 29(11). 881–889. 4 indexed citations
15.
Yilmaz, Emrullah, Nofisat Ismaila, Julie E. Bauman, et al.. (2022). Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. Journal of Clinical Oncology. 41(5). 1132–1146. 49 indexed citations
16.
Sterk, Rosa T., Joon‐Yong Chung, Kiersten L. Berggren, et al.. (2021). MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors. PLoS Pathogens. 17(1). e1009216–e1009216. 25 indexed citations
17.
18.
Coveler, Andrew L., David L. Bajor, Ashiq Masood, et al.. (2020). Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 38(15_suppl). TPS4671–TPS4671. 5 indexed citations
19.
Yilmaz, Emrullah, et al.. (2015). Emerging treatment for advanced lung cancer withEGFRmutation. Expert Opinion on Emerging Drugs. 20(4). 597–612. 21 indexed citations
20.
Yilmaz, Emrullah, Lauren A. Byers, Lixia Diao, et al.. (2012). Use of proteomic analysis of LKB1/AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB1 loss or mTOR inhibition in NSCLC: Implications for targeted combinations.. Journal of Clinical Oncology. 30(15_suppl). 10612–10612. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anuj Goenka Breakdown of academic impact, for papers by Rolf Warta Breakdown of academic impact, for papers by Timothy A. Chan Breakdown of academic impact, for papers by Debyani Chakravarty Breakdown of academic impact, for papers by Binish Rasheed Breakdown of academic impact, for papers by David Tran Breakdown of academic impact, for papers by Diana Mandelker Breakdown of academic impact, for papers by Koichi Yoshikawa Breakdown of academic impact, for papers by S. Fracchioli Breakdown of academic impact, for papers by Ingrid Moen
Rankless by CCL
2026